Investment Rating - The investment rating for the company is "Buy" (maintained) [1][5][13] Core Views - The company reported a revenue of 5.44 billion yuan in Q1 2025, representing a year-on-year increase of 20.91% and a quarter-on-quarter decrease of 6.66%. The net profit attributable to the parent company was 1.16 billion yuan, up 116.18% year-on-year and 0.05% quarter-on-quarter, driven by the increase in both volume and price of nutritional products [5] - The company maintains its profit forecast, expecting net profits of 6.69 billion yuan, 7.51 billion yuan, and 8.08 billion yuan for 2025-2027, with corresponding EPS of 2.18, 2.44, and 2.63 yuan per share [5] - The company is optimistic about its "Chemicals+" and "Biological+" strategic main channels, and is steadily advancing project construction [5] Financial Summary - Revenue for 2023 was 15.12 billion yuan, with a year-on-year decrease of 5.1%. For 2024, revenue is projected to be 21.61 billion yuan, a year-on-year increase of 43.0%, and for 2025, it is expected to reach 25.86 billion yuan, a year-on-year increase of 19.6% [7][9] - The net profit attributable to the parent company for 2023 was 2.70 billion yuan, with a year-on-year decrease of 25.3%. For 2024, it is projected to be 5.87 billion yuan, a year-on-year increase of 117.0%, and for 2025, it is expected to be 6.69 billion yuan, a year-on-year increase of 14.0% [7][9] - The gross margin for 2023 was 33.0%, expected to rise to 41.8% in 2024 and remain stable in 2025 [10] Market Conditions - The market prices for Vitamin A (VA), Vitamin E (VE), and solid egg products have shown significant year-on-year changes, with VA increasing by 37.4% and VE by 109.9% in Q1 2025 [5] - The domestic export volume of methionine in Q1 2025 was 79,000 tons, a year-on-year increase of 7.35% [5] Project Progress - The company has achieved full production capacity of 300,000 tons of solid egg products and is nearing completion of the construction of 180,000 tons/year of liquid egg products [5] - New projects in aldehyde series, SA projects, and the first phase of the fragrance industrial park are progressing steadily [5]

Group 1 - The company reported Q1 2025 revenue of 5.44 billion yuan, a year-on-year increase of 20.9% and a quarter-on-quarter decrease of 6.66% [1] - The net profit attributable to the parent company reached 1.88 billion yuan, a year-on-year increase of 116.2% and a slight quarter-on-quarter increase, achieving a new record high [1] - The significant growth in performance is primarily attributed to the rise in prices of Vitamin E (VE) and methionine, with expectations for sustained high prices due to improved supply and demand dynamics [1][3] Group 2 - The average prices for VA/VE/VC/methionine in Q1 were 112.3/136.4/28.3/20.9 yuan/kg, representing year-on-year increases of 37.4%/109.9%/15.6%/-4.2% [2] - The company maintained a stable operation with a period expense ratio of 7%, which has been decreasing both year-on-year and quarter-on-quarter [2] - The gross profit margin was 46.7%, an increase of 11.7 percentage points year-on-year, while the net profit margin was 34.7%, an increase of 13.3 percentage points year-on-year [2] Group 3 - The supply-demand improvement in the methionine and VE markets is expected to support high price levels, with DSM planning to exit the vitamin market and leading methionine producers reducing production [3] - Recent price increases for methionine and VE are anticipated to positively impact the company's performance, with each 1 yuan/kg increase in price expected to add approximately 280 million yuan and 45 million yuan to profits, respectively [3] - The new materials business is experiencing rapid growth, with investments in various projects expected to accelerate future growth [3] Group 4 - The company forecasts net profits attributable to the parent company of 7.87 billion, 9.38 billion, and 9.76 billion yuan for 2025-2027, with corresponding EPS of 2.56, 3.05, and 3.18 yuan [4] - The current price corresponds to a PE ratio of 8.7, 7.3, and 7.0 for the respective years, maintaining a "buy" rating [4]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company achieved a revenue of 5.44 billion yuan in Q1 2025, representing a year-on-year increase of 20.9% and a quarter-on-quarter decrease of 6.66%. The net profit attributable to the parent company reached 1.88 billion yuan, a year-on-year increase of 116.2% and a slight quarter-on-quarter increase, marking a new high in profitability. The significant growth in performance is primarily attributed to the price increases of Vitamin E (VE) and methionine [1][2] - The supply-demand dynamics for VE and methionine are improving, with prices expected to remain high due to the reduction in production capacity by overseas leaders. The recent price adjustments by major companies indicate a positive trend for future profitability [3][4] Summary by Sections Financial Performance - In Q1 2025, the average prices for VA/VE/VC/methionine were 112.3/136.4/28.3/20.9 yuan/kg, with year-on-year changes of 37.4%/109.9%/15.6%/-4.2% and quarter-on-quarter changes of -33.3%/-3.0%/-2.8%/+4.8%. The net profit margin was 34.7%, up 13.3 percentage points year-on-year and 2.3 percentage points quarter-on-quarter. Operating cash flow reached 1.596 billion yuan, a year-on-year increase of 2.32 times [2][3] Market Outlook - The report anticipates continued price increases for methionine and VE, driven by supply constraints from major producers. The current price of methionine is 22.1 yuan/kg, up 12.5% year-on-year. Each 1 yuan/kg increase in methionine and VE is expected to enhance the company's performance by 280 million yuan and 45 million yuan, respectively [3][4] Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are 7.867 billion, 9.383 billion, and 9.761 billion yuan, with corresponding EPS of 2.56, 3.05, and 3.18 yuan. The current price corresponds to a PE ratio of 8.7, 7.3, and 7.0 for the respective years [4]

Investment Rating - The report maintains an "Outperform" rating for the company [4][7]. Core Views - The market prices of the company's main products in the nutrition sector have recovered, leading to an upward revision of EPS forecasts for 2025 and 2026 to RMB 2.19 and RMB 2.44 respectively, with a new estimate for 2027 at RMB 2.63. A target price of RMB 30.66 is set based on a 14x PE for 2025 [4][7]. - The company is expected to achieve a revenue of RMB 21.61 billion in 2024, representing a year-on-year increase of 42.95%, and a net profit attributable to shareholders of RMB 5.87 billion, up 117.01% year-on-year [4][7]. - The first quarter of 2025 is projected to show significant growth, with net profit expected to be between RMB 1.8 billion and RMB 1.9 billion, reflecting a year-on-year increase of 107%-118% [4][7]. Financial Performance Summary - **Revenue Forecasts**: - 2023A: RMB 15,117 million - 2024A: RMB 21,610 million (up 43.0%) - 2025E: RMB 24,323 million (up 12.6%) - 2026E: RMB 27,763 million (up 14.1%) - 2027E: RMB 29,875 million (up 7.6%) [3][6]. - **Net Profit (Attributable to Shareholders)**: - 2023A: RMB 2,704 million - 2024A: RMB 5,869 million (up 117.0%) - 2025E: RMB 6,719 million (up 14.5%) - 2026E: RMB 7,502 million (up 11.7%) - 2027E: RMB 8,087 million (up 7.8%) [3][6]. - **Earnings Per Share (EPS)**: - 2023A: RMB 0.88 - 2024A: RMB 1.91 - 2025E: RMB 2.19 - 2026E: RMB 2.44 - 2027E: RMB 2.63 [3][6]. - **Return on Equity (ROE)**: - 2023A: 10.9% - 2024A: 20.0% - 2025E: 20.0% - 2026E: 19.6% - 2027E: 18.6% [3][6]. Sector Performance - The nutrition sector is expected to see revenue growth of 52.58%, while fragrances, new materials, and other products are projected to grow by 19.62%, 39.51%, and 24.33% respectively in 2024 [4][7]. - The gross profit margin changes for these sectors are +13.27 percentage points for nutrition, +1.33 percentage points for fragrances, -5.84 percentage points for new materials, and +7.49 percentage points for other products [4][7]. New Projects and Products - The nutrition sector has seen the release of methionine project capacity at 300,000 tons/year, with a joint venture for a liquid methionine project nearing completion. The company is also advancing in the fragrances and new materials sectors with various projects [8].

Financial Performance - The company's revenue for Q1 2025 reached ¥5,439,577,817.97, representing a year-on-year increase of 20.91% compared to ¥4,498,764,263.04 in the same period last year[5] - Net profit attributable to shareholders was ¥1,879,910,462.58, a significant increase of 116.18% from ¥869,622,923.96 in the previous year[5] - Basic earnings per share rose to ¥0.61, up 117.86% from ¥0.28 in the previous year[5] - Operating profit for the current period was ¥2,143,877,229.15, up 99.9% from ¥1,072,533,968.01 in the previous period[24] - Net profit attributable to the parent company was ¥1,879,910,462.58, a significant increase of 116.3% compared to ¥869,622,923.96 in the previous period[24] Cash Flow - The net cash flow from operating activities increased by 231.88%, amounting to ¥1,595,982,605.81, compared to ¥480,895,414.07 in the same period last year[5] - Cash inflow from operating activities totaled ¥5,715,288,486.58, an increase from ¥4,009,459,847.44 in the previous period[26] - The net cash flow from operating activities was CNY 1,595,982,605.81, a significant increase from CNY 480,895,414.07 in the previous period, representing a growth of approximately 232%[27] - Cash inflow from financing activities was CNY 572,494,106.93, down from CNY 1,130,900,749.27, a decrease of approximately 49%[27] - The net cash flow from financing activities was CNY -545,176,666.55, compared to a positive CNY 56,722,688.55 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥43,777,419,398.69, reflecting a 1.83% increase from ¥42,989,132,470.97 at the end of the previous year[5] - The company's current assets totaled CNY 18,034,022,364.43, up from CNY 16,922,201,085.10 at the start of the period, reflecting a growth of approximately 6.58%[20] - The total liabilities decreased to CNY 13,020,168,261.57 from CNY 13,543,582,208.04, showing a reduction of about 3.87%[21] - The company's total equity remained stable at CNY 30,757,421,680.00, unchanged from the previous period[21] Investment and Expenses - The company reported a 583.44% increase in investment income, primarily due to higher returns from joint ventures[14] - The company experienced a 246.21% decrease in financial expenses, attributed to increased foreign exchange gains[9] - Research and development expenses increased to ¥256,931,534.29, up from ¥202,953,832.19 in the previous period, reflecting a focus on innovation[23] - The company reported a significant reduction in financial expenses, with a net financial cost of -¥62,451,557.05 compared to ¥42,714,986.04 in the previous period[23] Changes in Cash and Equivalents - The company's cash and cash equivalents net increase decreased by 411.30%, mainly due to increased expenditures on bank wealth management products and special dividend payments[11] - The company's cash and cash equivalents decreased to CNY 7,464,811,535.54 from CNY 7,936,504,805.65, indicating a decline of about 5.93%[19] - The total cash and cash equivalents at the end of the period amounted to CNY 5,136,830,236.59, a decrease from CNY 4,570,125,619.38 year-over-year[27] Other Financial Metrics - The weighted average return on equity increased by 2.85 percentage points to 6.29% from 3.44% in the previous year[5] - Other comprehensive income after tax attributable to the parent company was ¥14,918,970.14, compared to a loss of ¥2,054,048.56 in the previous period[24] - The cash outflow for debt repayment was CNY 443,917,925.63, down from CNY 1,003,043,623.32, a decrease of about 56%[27] Corporate Actions - The company completed the absorption merger of its wholly-owned subsidiaries, increasing the registered capital of the surviving entity from CNY 400 million to CNY 900 million[17] - The company has not disclosed any related party transactions or significant asset restructuring in the recent period[17]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved significant growth in 2024, with total revenue reaching 21.61 billion yuan, a year-on-year increase of 42.95%, and a net profit attributable to shareholders of 5.87 billion yuan, up 117.01% year-on-year [4] - The first quarter of 2025 is expected to see a net profit of 1.8 billion to 1.9 billion yuan, representing a year-on-year growth of 107% to 118% [5] - The nutrition segment's performance was boosted by the release of new production capacity for methionine and a recovery in demand from the aquaculture industry, leading to a significant increase in revenue [6] Summary by Sections Financial Performance - In 2024, the nutrition segment generated revenue of 15.06 billion yuan, a 52.58% increase year-on-year, accounting for 69.67% of total revenue [6] - The average market prices for key products such as vitamins A, E, C, and methionine saw significant year-on-year increases, supporting revenue growth [6] - The company expects to achieve net profits of 6.52 billion, 7.33 billion, and 8.03 billion yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 10, 9, and 8 [10] Production Capacity and Projects - The company has fully released its 300,000-ton methionine production capacity, contributing to profit growth [7] - Ongoing projects include an 18,000-ton liquid methionine project and various expansions in the flavor and fragrance segment [9] Market Dynamics - The supply of key products remains tight due to production disruptions at major international manufacturers, which is expected to support price increases [6] - The recovery in the pig farming industry and significant growth in export volumes have notably boosted demand for vitamins [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved significant growth in 2024, with total revenue reaching 21.61 billion yuan, a year-on-year increase of 42.95%, and a net profit attributable to shareholders of 5.87 billion yuan, up 117.01% year-on-year [4] - The first quarter of 2025 is expected to see a net profit of 1.8 billion to 1.9 billion yuan, representing a year-on-year growth of 107% to 118% [5] - The nutrition segment's performance was boosted by the release of new production capacity for methionine and a recovery in demand from the aquaculture industry, alongside supply constraints from major international manufacturers [6][7] Summary by Sections Financial Performance - In 2024, the nutrition segment generated revenue of 15.06 billion yuan, a 52.58% increase year-on-year, accounting for 69.67% of total revenue [6] - The average market prices for key products such as vitamins A, E, C, and methionine saw significant increases, supporting revenue growth [6] - The company expects net profits for 2025-2027 to be 6.52 billion, 7.33 billion, and 8.03 billion yuan respectively, with corresponding P/E ratios of 10, 9, and 8 [10] Production Capacity and Projects - The company has fully released its 300,000-ton methionine production capacity, contributing to profit growth [7] - Ongoing projects include an 18,000-ton liquid methionine project and various expansions in the flavor and fragrance segment [9] Market Dynamics - The recovery in the pig farming industry and significant export growth have notably increased demand for vitamins A, E, and C, with export volumes rising by 28.96%, 35.82%, and 5.58% respectively [6] - The company is actively expanding its product matrix and enhancing its core competitiveness through various projects [9]

Investment Rating - The investment rating for the company has been upgraded to "Buy" due to a significant recovery in industry conditions and the company's position as a leading enterprise benefiting from this trend [2][5]. Core Views - The company's revenue for 2024 is projected to reach 21.61 billion yuan, representing a year-on-year growth of 43.0%. The net profit attributable to the parent company is expected to be 5.87 billion yuan, a 117.0% increase compared to the previous year [4][8]. - The recovery in the vitamin industry, particularly for Vitamin A and E, has led to a notable increase in prices, which has positively impacted the company's gross margin, reaching 43.18%, an increase of 13.27 percentage points from 2023 [8]. - The company is expected to continue benefiting from the increasing domestic share of the vitamin market, which has risen to approximately 86% in 2024, as overseas production declines due to various factors [8]. - New projects, such as the methionine project in collaboration with Sinopec, are anticipated to drive sustained growth for the company [8]. Financial Summary - Revenue (in million yuan): - 2023A: 15,117 - 2024A: 21,610 - 2025E: 23,641 - 2026E: 24,826 - 2027E: 26,496 - Year-on-year growth rates: - 2024: 43.0% - 2025: 9.4% - 2026: 5.0% - 2027: 6.7% [4][11] - Net profit (in million yuan): - 2023A: 2,704 - 2024A: 5,869 - 2025E: 6,271 - 2026E: 6,295 - 2027E: 6,957 - Year-on-year growth rates: - 2024: 117.0% - 2025: 6.9% - 2026: 0.4% - 2027: 10.5% [4][11] - Earnings per share (in yuan): - 2023A: 0.88 - 2024A: 1.91 - 2025E: 2.04 - 2026E: 2.05 - 2027E: 2.26 [4][11] - Target price is set at 28.56 yuan based on a 14x average PE ratio of comparable companies for 2025 [2][5].

Investment Rating - The investment rating for the company has been upgraded to "Buy" due to the significant recovery in the vitamin industry and the company's strong performance as a leading enterprise in the sector [2][5]. Core Views - The company reported a substantial increase in performance, with a revenue of 21.61 billion yuan in 2024, representing a year-on-year growth of 42.95%. The net profit attributable to the parent company reached 5.87 billion yuan, a year-on-year increase of 117.01%. This growth is primarily driven by the recovery in the vitamin A and E markets, which led to a notable increase in product prices and an improvement in the gross margin of the nutrition products segment to 43.18%, up 13.27 percentage points from 2023 [8]. - The vitamin production in China has been steadily increasing, accounting for approximately 86% of the total output by 2024. The decline in production from overseas companies due to various factors has contributed to the recovery of the vitamin industry, benefiting leading companies like this one [8]. - The company is pursuing new projects in collaboration with upstream petrochemical companies, such as the methionine project and nylon new materials project, which are expected to drive sustainable growth [8]. Financial Information Summary - Revenue (million yuan): 2023A: 15,117; 2024A: 21,610; 2025E: 23,641; 2026E: 24,826; 2027E: 26,496 [4] - Year-on-year growth in revenue: 2024A: 43.0%; 2025E: 9.4%; 2026E: 5.0%; 2027E: 6.7% [4] - Net profit attributable to the parent company (million yuan): 2023A: 2,704; 2024A: 5,869; 2025E: 6,271; 2026E: 6,295; 2027E: 6,957 [4] - Earnings per share (yuan): 2023A: 0.88; 2024A: 1.91; 2025E: 2.04; 2026E: 2.05; 2027E: 2.26 [4] - Target price set at 28.56 yuan based on a 14x average PE ratio of comparable companies [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002001 证券简称：新和成 公告编号：2025-023 浙江新和成股份有限公司 回购股份报告书 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、本次回购事项已经浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十一次会议审议通 过，以自有资金或回购专项贷款以集中竞价交易的方式回购公司部分社会公众股份，回购股份用于实施 股权激励计划或员工持股计划。本次回购金额区间为30,000万元-60,000万元，回购价格不超过人民币32 元/股。按本次回购资金总额上下限测算，预计回购股份区间为9,375,000股-18,750,000股，占公司总股 本的比例区间为0.31%-0.61%。具体回购股份的数量以回购期满时实际回购的股份数量为准。本次回购 股份期限为自董事会审议通过本回购方案之日起12个月。公司已在中国证券登记结算有限责任公司深圳 分公司开立回购专用证券账户。 2、风险提示： （1）本次回购方案可能面临因回购期限内公司股票价格持续超出回购价格上限等原因，导致本次回购 方案无法 ...